Singapore markets close in 6 hours 25 minutes

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
2.1000-0.0900 (-4.11%)
At close: 12:30PM EST
Currency in CAD

Valuation measures4

Market cap (intra-day) 25.92M
Enterprise value 1.64M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.10
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.09

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-68.26%
S&P500 52-week change 318.79%
52-week high 37.7500
52-week low 31.7200
50-day moving average 32.0880
200-day moving average 33.3472

Share statistics

Avg vol (3-month) 318.39k
Avg vol (10-day) 35.69k
Shares outstanding 514.24M
Implied shares outstanding 6N/A
Float 812.32M
% held by insiders 113.45%
% held by institutions 14.43%
Shares short (30 Dec 2021) 413.08k
Short ratio (30 Dec 2021) 40.63
Short % of float (30 Dec 2021) 40.95%
Short % of shares outstanding (30 Dec 2021) 40.09%
Shares short (prior month 29 Nov 2021) 413.72k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-52.08%
Return on equity (ttm)-3,934.83%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-19.41M
Diluted EPS (ttm)-1.8720
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)33.67M
Total cash per share (mrq)2.36
Total debt (mrq)9.38M
Total debt/equity (mrq)41.08
Current ratio (mrq)12.03
Book value per share (mrq)1.66

Cash flow statement

Operating cash flow (ttm)-11.2M
Levered free cash flow (ttm)-14.02M